Par Pharmaceuticals announced that it has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Fluphenazine Decanoate Injection.

Fluphenazine Decanoate is an antipsychotic indicated for the management of patients requiring prolonged parenteral neuroleptic therapy (eg, chronic schizophrenia). Fluphenazine is a piperazine phenothiazine that works by blocking postsynaptic mesolimbic dopaminergic receptors in the brain.

RELATED: Skull Chip Implant Research for Psych Disorders

Fluphenazine Decanoate Injection is available as a 25mg/mL strength in 5mL multi-dose flip-top vials. Par has begun shipping the product.

For more information call (800) 828-9393 or visit